Poxel stock soars 34.5% and breaks through its 0.20 € resistance level
Poxel stands out as an exception in a poorly oriented Paris trading session. The stock posts a spectacular jump, just hours after announcing a quarter marked by a surge in its royalties.
A resistance level broken intraday and the strongest gain on the entire Paris market
The price of Poxel reaches 0.20 € after a gain of 34.32% since the last close (0.15 €). The stock has broken through its resistance level, situated at 0.20 €, and is holding above it. This movement gives it the top position in the ranking of the strongest gains on the CAC All Shares index, ahead of Proactis (+18.1%). This occurs while the CAC 40 declines 1.36% and the SBF 120 falls 1.33%.
The momentum is clear over the week, with +34.33% over seven days. The price is back above its 20 and 50-day moving averages (MA20: +24.25% difference, MA50: +10.44%). The MA200, at 0.23 €, remains above the price, however, at a distance of 13.57%. The decline over one year is still 51.35%.
Royalties up 10% that become net positive for the first time
The company published on Monday revenue of 1,951 k€ in the third quarter of 2026, compared with 1,292 k€ a year earlier, representing growth of 51%. This is driven by increased Twymeeg sales in Japan. The crossing of the contractual threshold of 5 billion yen in net sales by Sumitomo Pharma raised the royalty rate from 8% to 10%, with retroactive effect on the fiscal year.
This new rate exceeds the 8% that Poxel pays back to Merck Serono. The group is therefore generating, for the first time, positive net royalties on the 2026 fiscal year from Sumitomo Pharma. These amounts are, however, entirely allocated to the repayment of obligations held by OrbiMed, under the royalty monetization agreement.
